1. Maher E, Kaelin WG. 1997 von Hippel-Lindau disease. Medicine 76:381-391
2. Friedrich CA. 2001 Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Gen 10 (7):763-767
3. Lonser RR, Glenn GM, Walther MM, Chew EY, Libutti SK, Linehan WM, Oldfield EH. 2003 von Hippel-Lindau disease. Lancet 361:2059-2067
4. Linehan WM & Klausner RD. Renal carcinoma. In: Vogelstein B (ed.). The genetic basis of human cancer. 1998 (first edition) and 2002 (second edition)
5. Neumann, H.P. & O.D. Wiestler. 1991 Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337: 1052-1054
6. Zbar B., T. Kishida, F. Chen, et al. 1996 Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8: 348-57.
7. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours: Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon
8. Filling-Katz MR, Choyke PL, Oldfield E, et al. 1991 Central nervous system involvement in von Hippel-Lindau disease. Neurology 41:41-46
9. Butman JA, Linehan WM, Lonser RR. Neurologic manifestations of von Hippel-Lindau disease. JAMA 2008;300(11):1334-1342
10. Neumann HP, Eggert H, Weigel K, et al. 1989 Hemangioblastomas of the central nervous system: a ten year study with spezial reference to von Hippel-Lindau syndrome. J Neurosurg 70:24-30
11. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. 2003 The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98:82-94
12. Vortmeyer AO, Yuan Q, Lee YS, Zhuang Z, Oldfield EH. 2004 Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol 55:721-728
13. Shively SB, Beltaifa S, Gehrs B, Duong H, Smith J, Edwards NA, Lonser RR, Raffeld M, Vortmeyer AO. Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J Pathol 2008;216(4):514-520
14. Chan CC, Collins AB, Chew EY. Molecular pathology of eyes with von Hippel-Lindau disease: a review. Retina. 2007 Jan;27(1):1-7
15. Schmid D, Natt E, Neumann HP. 2000 Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. Eur J Med Res 5:47-58
16. Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah AL, Kaelin WG Jr. Rapid and durable recovery of visual function in a patient with von Hippel Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology. 2002 Sep;109(9):1745-51
17. Girmens JF, Erginay A, Massin P, Scigalla P, Gaudric A, Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol. 2003 Jul;136(1):194-6.
18. Wong WT, Chew EY. Ocular von Hippel-Lindau disease: clinical update and emerging treatments. Curr Opin Ophthalmol. 2008 May;19(3):213-7
19. Wong WT, Agró, Coleman HR, Tran T, Reed GF, Csaky K, Chew EY. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. Ophthalmology. 2008 Jan;115(1):181-8
20. Chew EY. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc. 2005;103:495-511.
21. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. 1996 Allelic deletion of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149:2089-2094
22. Neumann HP, Riegler P, Huber W, et al. 2001 The challenge of kidney lesions in von Hippel-Lindau disease. Contrib Nephrol 136:193-207
23. Richard S., D. Chaveau, Y. Chretien et al. 1994 Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol 23: 1-27
24. Grubb RL, Choyke PL, Pinto PA, Linehan WM, Walther MM. 2005 Management of von Hippel-Lindau associated kidney cancer. Nat Clin Pract Urol 2:248-255
25. Kaelin WG Jr. 2004 The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10:6290S-5S
26. Linehan WM, Vaselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L. 2004 Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10:6282S-9S
27. Choyke PL, Glenn GM, Walther MM, et al. 1995 Von Hippel-Lindau disease: genetic, clinical and imaging features. Radiology 194:629-636
28. Poston CD, Jaffe GS, Lubensky IA, et al. 1995 Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153:22-30
29. Jamis-Dow CA, Choyke PL, Jennings SB, et al. 1996 Small (<3 cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 198:785-790
30. Walther MM, Choyke PL, Weiss G, et al. 1995 Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 153:913-916
31. Choyke PL, Glenn G, Walther MM, et al. 1992 The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR 159:1229-1234
32. Neumann HP, Bender BU, Berger DP, et al. 1998 Prevalence, morphology, and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 160:1248-1254
33. Chretien Y, Chauveau D, Richard S, Droz D, Correas JM, et al. 1997 Treatment of von Hippel-Lindau disease with renal involvement. Prog Urol 7:939-947
34. Ploussard G, Droupy S, Ferlicot S, Ples R, Rocher L, Richard S, Benoit G. Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease. Urology 2007;70(3):435-439
35. Lehman DS, Landman J. Cryoablation and radiofrequency for kidney tumor. Curr Urol Rep 2008; 9(2):128-134
36. Chen VH, Mayes JM, Madden JF, Stein AJ, Mouraviev V, Polascik TJ. The effect of cryoablation on the histologic interpretation of intraoperative biopsy of small clear cell renal carcinoma and renal oncocytoma. J Endourol 2008;22(8):1617-1621
37. Koch, C.A., D. Mauro, M.M. Walther et al. 2002 Pheochromocytomas in VHL disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocrine Pathol 13(1):17-27
38. Walther M.M., R. Reiter, H.R. Keiser et al. 1999. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162: 659-664
39. Timmers HJ, Pacak K, Huynh TT, Abu-Asab M, Tsokos M, Merino MJ, Baysal BE, Adams KT, Eisenhofer G. Biochemically silent abdominal paragangliomas in patients with mutations in the SDHB gene. J Clin Endocrinol Metab. 2008
40. Neumann H.P., D.P. Berger, G. Sigmund et al. 1993 Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329: 1531-1538
41. Sato Y, Waziri M, Smith W, Frey E: Hippel-Lindau disease: MR imaging. Radiology 1988;166:241-246
42. Atuk NO, McDonald T, Wood T, Carpenter JT, Walzak MP, Donaldson M, Gillenwater JY: Familial pheochromocytoma, hypercalcemia, and von Hippel-Lindau disease. A ten year study of a large family. Medicine (Baltimore) 1979; 58:208
43. Walther M.M., Herring J., Enquist E., et al. 1999 Von Recklinghausen.s disease and pheochromocytomas. J Urol 162, 1582-1586
44. Pacak K., Chrousos GP, Koch CA, Eisenhofer G. Pheochromocytoma: progress in diagnosis, therapy, and genetics. In Adrenal Disorders. A. Margioris & G.P. Chrousos, Eds.: 379-413. Humana Press. New York, NY, 2001
45. Koch CA, Vortmeyer AO, Diallo R, et al. 2002 Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 146:381-388
46. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP, Plouin PF. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007 Oct;92(10):3822-8
47. Eisenhofer G, Lenders JW, Linehan WM, et al. 1999 Plasma normetanephrine and metanephrine for detecting pheochromocytomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879
48. Lenders JWM, Pacak K, Walther MM, et al. 2002 Biochemical diagnosis of pheochromocytoma. Which is the best test ? JAMA 287:1427-1434
49. Hes FJ, Hoppener JW, Lips CJ. 2003 Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab 88:969-974
50. Weise M, Merke DP, Pacak K, et al. 2002 Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab 87:1955-1960
51. Havekes B, Romijn JA, Eisenhofer G, Adams K, Pacak K. Update on pediatric pheochromocytoma. Pediatr Nephrol. 2008
52. Pacak K, Linehan WM, Eisenhofer G, et al. 2001 Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315-329
53. Koch CA. Should 123I-labeled meta-iodobenzylguanide scintigraphy be part of the imaging work-up for pheochromocytoma ? Nat Clin Pract Endocrinol Metab 2009
54. Maher E.R., J.R. Yates, R. Harries et al. 1990 Clinical features and natural history of von Hippel-Lindau disease. Quart J Med 77: 1151-63
55. Ritter M.M., A. Frilling, P.A. Crossey et al. 1996 Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 81: 1035-7
56. Eisenhofer G, Walther MM, Huynh TT, et al. 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 86:1999-2008
57. Neumann HP, Bausch B, McWhinney, et al. 2002 Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
58. Pavlovich CP, Linehan WM, Walther MM. 2001 Partial adrenalectomy in patients with multiple adrenal tumors. Curr Urol Rep 2:19-23
59. Walther MM, Keiser HR, Linehan WM. 1999 Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol 17:35-39
60. Brunt LM, Lairmore TC, Doherty GM, et al. 2002 Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg 235:713-721
61. Neumann HP, Bender BU, Reincke M, et al. 1999 Adrenal sparing surgery for pheochromocytoma. Br J Surg 84:94-97
62. Bausch B, Borozdin W, Neumann HP. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 2006;354(25):2729-2731
63. Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK, Lamesch P, Ott R, Kluge R, Bierbach U, Tannapfel A. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy ? Ann NY Acad Sci 2006;1073:517-526
64. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease related tumors. J Clin Endocrinol Metab 2008
65. Choyke PL, Glenn GM, Wagner JP, et al. 1997 Epididymal cystadenomas in von Hippel-Lindau disease. Urology 49:926-931
66. Mehta GU, Shively SB, Duong H, Tran MG, Moncrief TJ, Smith JH, Li J, Edwards NA, Lonser RR, Zhuang Z, Merrill MJ, Raffeld M, Maxwell PH, Oldfield EH, Vortmeyer AO. Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease. Neoplasia. 2008 Oct;10(10):1146-53
67. Neumann HP, Dinkel E, Brambs H, et al. 1991 Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 101:465-471
68. Hough MT, Stephens DH, Johnson CD, Binkovitz LA. 1994 Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. Am J Roentgenol 162:1091-1094
69. Binkovitz LA, Johnson CD, Stephens DH. 1990 Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. Am J Roentgenol 155:501-505
70. Lubenksy IA, Pack SD, Ault D, et al. 1998 Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients. Am J Pathol 153:223-231
71. Libutti SK, Choyke PL, Bartlett DL, et al. 1998 Pancreatic neuroendocrine tumors associated with von Hippel-Lindau: diagnostic and management recommendations. Surgery 124:1153-1159
72. Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL. 2002 Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology 225:751-8
73. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease manifested by pancreatic neuroendocrine neoplasms. Surgery. 2007 Dec;142(6):814-8
74. Cornish D, Pont A, Minor D, et al. 1984 Metastatic islet cell tumor in von Hippel-Lindau disease. Am J Med 77:147-150
75. Corcos O, Couvelard A, Giraud S, Vullierme MP, Dermot O'Toole, Rebours V, Stievenart JL, Penfornis A, Niccoli-Sire P, Baudin E, Sauvanet A, Levy P, Ruszniewski P, Richard S, Hammel P. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas. 2008 Jul;37(1):85-93
76. Manski TJ, Heffner DK, Glenn GM, et al. 1997 Endolymphatic sac tumors: a source of morbid hearing loss in von Hippel-Lindau disease. JAMA 277:1461-1465
77. Glasker S, Lonser RR, Tran MG, Ikejiri B, Butman JA, Zeng W, Maxwell PH, Zhuang Z, Oldfield EH, Vortmeyer AO. 2005 Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res 65:10847-53
78. Lonser RR, Baggenstos M, Kim HJ, Butman JA, Vortmeyer AO. The vestibular aqueduct: site of origin of endolymphatic sac tumors. J Neurosurg. 2008 Apr;108(4):751-6
79. Tay KY, Yu E, Kassel E. Spinal metastasis from endolymphatic sac tumor. AJNR Am J Neuroradiol 2007;2894):613-614
80. Megerian CA, Haynes DS, Poe DS, et al. 2002 Hearing preservation surgery for small endolymphatic sac tumors in patients with von Hippel-Lindau syndrome. Otol Neurotol 23:378-387
81. Kim HJ, Butman JA, Brewer C, Zalewski C, Vortmeyer AO, Glenn G, Oldfield EH, Lonser RR. 2005 Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg 102:503-12
82. Kempermann G, Neumann HP, Volk B. 1998 Endolymphatic sac tumors. Histopathology 33:2-10
83. Latif F, Tory K, Gnarra J, et al. 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320
84. Kaelin WG Jr. 2002 Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-82
85. Stolle C, Glenn G, Zbar B, et al. 1998 Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417-423
86. Vortmeyer AO, Huang SC, Pack SD, Koch CA, et al. 2002 Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 21: 1167-1170
87. Kondo, K. & W.G. Kaelin. 2001 The von Hippel-Lindau tumor suppressor gene. Exp. Cell Res. 264: 117-125
88. Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PloS One 2008;3(11):3801
89. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008 Nov;8(11):865-73
90. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol. 2006 Dec 10;24(35):5593-600
91. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s
92. Bender B.U., M. Gutsche, S. Glasker, et al. 2000 Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85: 4568-4574
93. Khosla S., V.M. Patel, I.D. Hay et al. 1991 Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest 87: 1691-1699
94. Zeiger, M.A., B. Zbar, H. Keiser et al. 1995 Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer 13: 151-156
95. Gnarra J, Ward J, Porter F, et al. 1997 Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 94:9102-9107
96. Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM, Pacak K. 2002 New insights into the genetics of familial chromaffin cell tumors. Ann NY Acad Sci 970:11-28
97. Brauer VH, Scholz GH, Neumann S, Lohmann T, Paschke R, Koch CA. 2004 RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70: should thyroidectomy be performed ? Endocr Practice 10 (1): 5-9
98. Ye L, Santarpia L, Cote GJ, El-Naggar AK, Gagel RF. High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2008 Nov;93(11):4367-72
99. Vortmeyer AO, Huang SC, Koch CA, et al. 2000 Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Cancer Res 60:5963-5965
100. Lee JY, Dong SM, Park WS, et al. 1998 Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 58:504-508
101. Koch CA, Huang SC, Zhuang Z, et al. 2002 Somatic VHL gene deletion and point mutation in MEN 2-associated pheochromocytoma. Oncogene 21:479-482
102. Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP, Paschke R. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006 May 17;6:131
103. Shuin T, Kondo K, Ashida S, et al. 1999 Germline and somatic mutations in the von Hippel-Lindau disease gene and its significance in the development of kidney cancer. Contrib Nephrol 128:1-10
104. Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S. Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med 2007 Nov-Dec;11(6):1408-15